Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 76

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 76
---
/09/2030 |                        |       — |            |                                                                |         — |     |                                                               |       — |     |                                                                                                     |         — |     |                                                                                                                     |   |
| 12/10/2021          |     |                           |  31,912 |     |                     | 10,638 |                                                                     |     | 40.52 |                                                                       |                       |      | 12/09/2031 |                        |   6,170 |            |                                                                |   164,431 |     |                                                               |       — |     |                                                                                                     |         — |     |                                                                                                                     |   |
| 12/9/2022           |     |                           |       — |     |                     |      — |                                                                     |     |     — |                                                                       |                       |    — |            |                        |  31,922 |            |                                                                |   850,721 |     |                                                               |       — |     |                                                                                                     |         — |     |                                                                                                                     |   |
| 12/23/2022          |     |                           |       — |     |                     |      — |                                                                     |     |     — |                                                                       |                       |    — |            |                        |  10,640 |            |                                                                |   283,556 |     |                                                               |       — |     |                                                                                                     |         — |     |                                                                                                                     |   |
| 3/4/2024            |     |                           |       — |     |                     |      — |                                                                     |     |     — |                                                                       |                       |    — |            |                        |  55,243 |            |                                                                | 1,472,226 |     |                                                               |  18,414 |     |                                                                                                     |   490,733 |     |                                                                                                                     |   |

(1) All of the option awards were granted under either the 2008 Plan, the 2018 Plan or the 2019 Plan and all of the stock awards were granted under the 2019 Plan. Additional information on our equity plans is set forth in Note 15 to our consolidated financial statements appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

#### 70Castle Biosciences 2025 Proxy Statement

#### Executive Compensation Tables
(2) Except for the options to purchase 65,627 shares of common stock granted to Mr. Maetzold with a vesting commencement date